Machine Learning Identified Distinct THC and CBD Biomarker Signatures in Saliva of Children With Autism Receiving Medical Cannabis
Machine learning analysis of saliva metabolomics from children with autism found that medical cannabis treatment shifted biomarker levels toward typically developing children, with THC and CBD each producing distinct metabolic signatures.
Quick Facts
What This Study Found
Lysophosphatidylethanolamine distinguished ASD from typically developing groups. THC-associated and CBD-associated cannabis-responsive biomarkers formed two distinct groups, while CBG was associated with biomarkers from both. Novel phytochemicals beyond THC/CBD were identified as contributing to therapeutic effects through acetylcholinesterase inhibition. Medical cannabis treatment shifted biomarker levels in children with ASD toward typically developing levels.
Key Numbers
Lysophosphatidylethanolamine identified as ASD-TD distinguishing biomarker. THC and CBD biomarker groups distinct. CBG overlaps both groups. Novel phytochemicals identified as acetylcholinesterase inhibitors.
How They Did This
Machine learning techniques applied to dynamic, high-resolution salivary metabolomics data from children with ASD before and after medical cannabis treatment and a typically developing control group.
Why This Research Matters
This is the first application of machine learning to cannabis-responsive biomarkers in autism. Finding distinct THC and CBD metabolic signatures and that treatment shifts ASD biomarkers toward typical levels provides a potential framework for personalizing cannabis treatment and measuring response.
The Bigger Picture
If validated, salivary biomarkers could provide an objective way to measure whether medical cannabis is working for a child with ASD, replacing subjective symptom ratings. The acetylcholinesterase inhibition finding also suggests a mechanism beyond just THC/CBD effects.
What This Study Doesn't Tell Us
Small sample size. Machine learning with limited data risks overfitting. Saliva metabolomics is an emerging field with limited validation. Cannot determine if biomarker changes cause clinical improvement. No placebo control.
Questions This Raises
- ?Can salivary biomarkers guide medical cannabis dosing for autism?
- ?Do the novel phytochemicals beyond THC/CBD contribute meaningfully to clinical improvement?
Trust & Context
- Key Stat:
- THC and CBD produce distinct metabolic biomarker signatures in saliva of autistic children
- Evidence Grade:
- Novel machine learning approach with limited sample, providing proof-of-concept requiring larger validation.
- Study Age:
- Published 2023.
- Original Title:
- A machine learning approach for understanding the metabolomics response of children with autism spectrum disorder to medical cannabis treatment.
- Published In:
- Scientific reports, 13(1), 13022 (2023)
- Authors:
- Quillet, Jean-Christophe, Siani-Rose, Michael(3), McKee, Robert(2), Goldstein, Bonni, Taylor, Myiesha, Kurek, Itzhak
- Database ID:
- RTHC-04858
Evidence Hierarchy
Watches what happens naturally without intervening.
What do these levels mean? →Frequently Asked Questions
Can we measure if medical cannabis is working for autism?
This study found that salivary biomarkers shifted toward typical levels after medical cannabis treatment in children with ASD, potentially providing an objective way to assess response.
Do THC and CBD affect autism differently?
Machine learning analysis found THC and CBD each produced distinct patterns of metabolic biomarker changes, while CBG showed overlap with both, suggesting each cannabinoid has a unique biological signature.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-04858APA
Quillet, Jean-Christophe; Siani-Rose, Michael; McKee, Robert; Goldstein, Bonni; Taylor, Myiesha; Kurek, Itzhak. (2023). A machine learning approach for understanding the metabolomics response of children with autism spectrum disorder to medical cannabis treatment.. Scientific reports, 13(1), 13022. https://doi.org/10.1038/s41598-023-40073-0
MLA
Quillet, Jean-Christophe, et al. "A machine learning approach for understanding the metabolomics response of children with autism spectrum disorder to medical cannabis treatment.." Scientific reports, 2023. https://doi.org/10.1038/s41598-023-40073-0
RethinkTHC
RethinkTHC Research Database. "A machine learning approach for understanding the metabolomi..." RTHC-04858. Retrieved from https://rethinkthc.com/research/quillet-2023-a-machine-learning-approach
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.